Next Article in Journal
Smoking and COVID-19: Adding Fuel to the Flame
Previous Article in Journal
Molecular Mechanisms of Reconsolidation-Dependent Memory Updating
Open AccessReview

mRNA Vaccine Era—Mechanisms, Drug Platform and Clinical Prospection

by Shuqin Xu 1,†, Kunpeng Yang 1,†, Rose Li 2 and Lu Zhang 1,3,*
1
State Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Science, Fudan University, Shanghai 200438, China
2
M.B.B.S., School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China
3
Shanghai Engineering Research Center of Industrial Microorganisms, Shanghai 200438, China
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Int. J. Mol. Sci. 2020, 21(18), 6582; https://doi.org/10.3390/ijms21186582
Received: 30 July 2020 / Revised: 26 August 2020 / Accepted: 30 August 2020 / Published: 9 September 2020
(This article belongs to the Special Issue Co-solvent Simulations in Drug Design)
Messenger ribonucleic acid (mRNA)-based drugs, notably mRNA vaccines, have been widely proven as a promising treatment strategy in immune therapeutics. The extraordinary advantages associated with mRNA vaccines, including their high efficacy, a relatively low severity of side effects, and low attainment costs, have enabled them to become prevalent in pre-clinical and clinical trials against various infectious diseases and cancers. Recent technological advancements have alleviated some issues that hinder mRNA vaccine development, such as low efficiency that exist in both gene translation and in vivo deliveries. mRNA immunogenicity can also be greatly adjusted as a result of upgraded technologies. In this review, we have summarized details regarding the optimization of mRNA vaccines, and the underlying biological mechanisms of this form of vaccines. Applications of mRNA vaccines in some infectious diseases and cancers are introduced. It also includes our prospections for mRNA vaccine applications in diseases caused by bacterial pathogens, such as tuberculosis. At the same time, some suggestions for future mRNA vaccine development about storage methods, safety concerns, and personalized vaccine synthesis can be found in the context. View Full-Text
Keywords: mRNA; mRNA vaccine; in vitro transcription; self-adjuvanting property; delivery carriers; infectious diseases; cancer therapeutics mRNA; mRNA vaccine; in vitro transcription; self-adjuvanting property; delivery carriers; infectious diseases; cancer therapeutics
Show Figures

Figure 1

MDPI and ACS Style

Xu, S.; Yang, K.; Li, R.; Zhang, L. mRNA Vaccine Era—Mechanisms, Drug Platform and Clinical Prospection. Int. J. Mol. Sci. 2020, 21, 6582.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop